A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

BACKGROUND: Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin–kexin type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol. METHODS: In this phase 1 trial, we randomly assi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Fitzgerald, Kevin, White, Suellen, Borodovsky, Anna, Bettencourt, Brian R., Strahs, Andrew, Clausen, Valerie, Wijngaard, Peter, Horton, Jay D., Taubel, Jorg, Brooks, Ashley, Fernando, Chamikara, Kauffman, Robert S., Kallend, David, Vaishnaw, Akshay, Simon, Amy
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5778873/
https://ncbi.nlm.nih.gov/pubmed/27959715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1609243
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars